# An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

> **NCT00613327** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 345 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Oxybutynin chloride OROS

## Key facts

- **NCT ID:** NCT00613327
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613327, "An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00613327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*